Physician

Robert J Ellis, M.D.

According to 2025 Medicare claims, Robert Ellis, M.D. (NPI: 1720056823) practices hematology/oncology in the Springfield, MO market, with the plurality of this provider's patient population coming from Greene, MO. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 65807-5230. Ellis is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Ellis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 597 traditional Medicare patients, billed 171,321 HCPCS/CPT codes, and received $4,901,291 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,847 prescription claims across 390 beneficiaries totaling $8,145,727 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 35 claims. Open Payments data shows 14 records totaling $10,410. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,221,105 to $4,901,291. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $4,101,389 and ending at $8,145,727. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,764 to $9,102.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	634	121,624	$2,221,105
2016	756	120,576	$2,170,409
2017	686	165,286	$2,624,515
2018	747	135,475	$2,451,440
2019	689	114,481	$2,229,639
2020	599	131,141	$2,941,996
2021	601	125,436	$3,148,381
2022	570	181,106	$3,574,607
2023	555	162,640	$4,098,933
2024	597	171,321	$4,901,291

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	329	3,169	$4,101,389
2016	320	3,073	$3,626,021
2017	351	3,363	$4,013,185
2018	356	3,303	$5,551,164
2019	303	2,774	$5,509,111
2020	313	2,428	$3,522,279
2021	334	2,228	$3,545,935
2022	353	2,421	$4,852,524
2023	379	2,582	$5,609,222
2024	390	2,847	$8,145,727

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	49	336	$71,194
2016	N/R	135	$37,848
2017	N/R	43	$11,286
2018	N/R	53	$7,889
2019	N/R	52	$31,805
2020	N/R	13	$2,092
2021	N/R	14	$1,591
2022	N/R	93	$4,334
2023	N/R	31	$2,178
2024	N/R	35	$2,217

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	267	725	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	351	774	$60
80053	Blood test, comprehensive group of blood chemicals	224	742	$10
36415	Insertion of needle into vein for collection of blood sample	420	1,345	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	445	1,661	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	71	1,967	$1,582,262
Imbruvica	Ibrutinib	61	1,716	$906,139
Revlimid	Lenalidomide	35	966	$594,074
Brukinsa	Zanubrutinib	29	866	$425,467
Erleada	Apalutamide	26	780	$388,647

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$1,590
E1392	Portable oxygen concentrator, rental	Y	N/R	11	$401
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	13	$410	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$10,000	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert J. Ellis, M.D.?

Tedicare shows public-source Medicare data for Robert J. Ellis, M.D. (NPI 1720056823), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert J. Ellis, M.D. have ACO affiliation data?

Robert J. Ellis, M.D. is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Robert J. Ellis, M.D.?

Robert J. Ellis, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Robert J. Ellis, M.D. have Open Payments data?

Robert J. Ellis, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.